Data presented at EASD found the daily orforglipron pill had cardiovascular safety comparable to daily glargine shots in higher-risk adults with type 2 diabetes.
Recap by typeshit. Full story at HealthDay on MSN.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
Avi Roy points to trial data on drugs like Ozempic, including a 16-week study of 73 people where milkshake ratings barely changed despite reduced appetite.
Research presented at the anesthesiology meeting linked GLP-1 use with lower odds of heart attack and other heart problems. It shows an association, not proof of cause.
A new study, shared by Medical Update Online, tracks a steep rise in GLP-1 drugs being prescribed to women who recently gave birth.
Approved on the 7th after a Phase 3 trial showing 9.75% average weight loss. Observers expect the lowest dose could cost around 100,000 won a month.
Loading…